# A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy

Study · id `cardio:ct-nct06979362` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06979362](<https://clinicaltrials.gov/study/NCT06979362>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06979362

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.

## Technical summary

Registry record NCT06979362. Randomized; quadruple masking; primary purpose treatment. Start 2025-06-27 (actual); primary completion 2027-11-16 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT06979362, source copy `cardio:ctgov-nct06979362-2026-10-05`, retrieved 2026-10-26)
- Started: 2025-06-27 (actual) (ClinicalTrials.gov record NCT06979362, source copy `cardio:ctgov-nct06979362-2026-10-05`, retrieved 2026-10-26)
- Primary completion: 2027-11-16 (anticipated) (ClinicalTrials.gov record NCT06979362, source copy `cardio:ctgov-nct06979362-2026-10-05`, retrieved 2026-10-26)
- Completion: 2028-07-25 (anticipated) (ClinicalTrials.gov record NCT06979362, source copy `cardio:ctgov-nct06979362-2026-10-05`, retrieved 2026-10-26)
- Countries: United States; Canada; Germany; India; Japan; Poland; South Korea; Spain; United Kingdom (ClinicalTrials.gov record NCT06979362, source copy `cardio:ctgov-nct06979362-2026-10-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06979362-2026-10-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
- Acronym: 8212-Preserved
- Condition: Heart Failure
- Intervention (Drug): CDR132L
- Intervention (Drug): Placebo
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

## Provenance

Content hash: 90a69ed725c69e47eb49edb0e7178b0f2b8539238a267b65e30185a95fec2040
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
